These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7493550)

  • 1. Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-counting.
    Pike VW; Aigbirhio FI; Freemantle CA; Page BC; Rhodes CG; Waters SL; Jones T; Olsson P; Ventresca GP; Tanner RJ
    Drug Metab Dispos; 1995 Aug; 23(8):832-9. PubMed ID: 7493550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of HFA134a.
    Ventresca GP
    J Aerosol Med; 1995; 8 Suppl 1():S35-9. PubMed ID: 10150494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure.
    Emmen HH; Hoogendijk EM; Klöpping-Ketelaars WA; Muijser H; Duistermaat E; Ravensberg JC; Alexander DJ; Borkhataria D; Rusch GM; Schmit B
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):22-35. PubMed ID: 11029265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.
    Kirby SM; Smith J; Ventresca GP
    Thorax; 1995 Jun; 50(6):679-81. PubMed ID: 7638815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of propellants.
    Alexander DJ
    J Aerosol Med; 1995; 8 Suppl 1():S29-34. PubMed ID: 10150492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation.
    Alexander DJ; Libretto SE; Chevalier HJ; Imamura T; Pappritz G; Wilson J
    Hum Exp Toxicol; 1995 Sep; 14(9):706-14. PubMed ID: 8579880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane).
    Alexander DJ; Libretto SE
    Hum Exp Toxicol; 1995 Sep; 14(9):715-20. PubMed ID: 8579881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The change to non-CFC metered dose inhalers.
    Rubinfeld A
    Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of fluorine-18-labeled 5-HT1A antagonists.
    Lang L; Jagoda E; Schmall B; Vuong BK; Adams HR; Nelson DL; Carson RE; Eckelman WC
    J Med Chem; 1999 May; 42(9):1576-86. PubMed ID: 10229627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Route-dependent comparative metabolism of [14C]toluene 2,4-diisocyanate and [14C]toluene 2,4-diamine in Fischer 344 rats.
    Timchalk C; Smith FA; Bartels MJ
    Toxicol Appl Pharmacol; 1994 Feb; 124(2):181-90. PubMed ID: 8122263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing aerosol delivery by pressurized metered-dose inhalers.
    Rubin BK; Fink JB
    Respir Care; 2005 Sep; 50(9):1191-200. PubMed ID: 16122402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers.
    Affrime MB; Cuss F; Padhi D; Wirth M; Pai S; Clement RP; Lim J; Kantesaria B; Alton K; Cayen MN
    J Clin Pharmacol; 2000 Nov; 40(11):1227-36. PubMed ID: 11075308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol therapy: assume nothing and require data.
    Anderson PJ
    Respir Care; 2003 Nov; 48(11):1016-8. PubMed ID: 14585111
    [No Abstract]   [Full Text] [Related]  

  • 15. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
    Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
    J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of radioactivity in fischer 344 rats after single and multiple inhalation exposure to [(14)C]Octamethylcyclotetrasiloxane ([(14)C]D(4)).
    Plotzke KP; Crofoot SD; Ferdinandi ES; Beattie JG; Reitz RH; McNett DA; Meeks RG
    Drug Metab Dispos; 2000 Feb; 28(2):192-204. PubMed ID: 10640518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technique for determination of human zinc absorption from measurement of radioactivity in a fecal sample or the body.
    Payton KB; Flanagan PR; Stinson EA; Chodirker DP; Chamberlain MJ; Valberg LS
    Gastroenterology; 1982 Dec; 83(6):1264-70. PubMed ID: 6813186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distribution and biological half-time of 203Hg in the human body according to a modified whole-body counting technique.
    Hattula T; Rahola T
    Environ Physiol Biochem; 1975; 5(4):252-7. PubMed ID: 809264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant design for the 1,1,1,2-tetrafluoroethane-water interface: ab initio calculations and in situ high-pressure tensiometry.
    Selvam P; Peguin RP; Chokshi U; da Rocha SR
    Langmuir; 2006 Oct; 22(21):8675-83. PubMed ID: 17014104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.